Thus, on the one hand, SSAO substrates active on adipocytes might limit lipid mobilization and could alleviate the risk of noxious complications of obesity and diabetes, as a consequence of insulin resistance and ectopic lipid deposition. The gene discussed is AOC2; the disease is obesity disorder.